Reported results
- Q4 fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in Q4 fiscal 2025; full year fiscal 2026 net revenue decreased 13.3% to $57.6 million from $66.4 million in fiscal 2025
- EXXUA net revenue was $6.6 million in full year fiscal 2026 (first full year of commercialization) and $3.9 million in Q4 fiscal 2026
- Q4 fiscal 2026 EXXUA prescriptions totaled 3,323, up approximately 138% from 1,398 in Q3 fiscal 2026
- Full year fiscal 2026 GAAP net loss of ($14.3 million), or ($1.16) per share basic and diluted, compared to ($13.6 million), or ($2.16) per share, in fiscal 2025
- Adjusted EBITDA (non-GAAP) was ($3.7) million for full year fiscal 2026 compared to $9.2 million in fiscal 2025; Q4 fiscal 2026 Adjusted EBITDA (non-GAAP) was $0.5 million compared to $2.0 million in Q4 fiscal 2025
- Cash and cash equivalents were $26.3 million at June 30, 2026, compared to $31.0 million at June 30, 2025
Notes
On March 31, 2026, the Company amended and restated certain warrants, reducing derivative warrant liabilities by $26.4 million and increasing stockholders’ equity by that same amount. Full year fiscal 2026 results included a $4.7 million derivative warrant liabilities loss, while full year fiscal 2025 included $8.3 million of impairment expense, $2.1 million of restructuring costs and a $1.7 million derivative warrant liabilities loss.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-09-22 (8-K, Item 2.02). Read the original filing on sec.gov.
